- Home
- LGVN vs BIVI Comparison
LGVN vs BIVI Comparison
Compare LGVN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- BIVI
- Stock Information
- Founded
- LGVN 2014
- BIVI 2013
- Country
- LGVN United States
- BIVI United States
- Employees
- LGVN N/A
- BIVI N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- BIVI Health Care
- Exchange
- LGVN Nasdaq
- BIVI Nasdaq
- Market Cap
- LGVN 17.6M
- BIVI 14.2M
- IPO Year
- LGVN 2021
- BIVI N/A
- Fundamental
- Price
- LGVN $0.63
- BIVI $1.33
- Analyst Decision
- LGVN Strong Buy
- BIVI
- Analyst Count
- LGVN 2
- BIVI 0
- Target Price
- LGVN $6.50
- BIVI N/A
- AVG Volume (30 Days)
- LGVN 388.1K
- BIVI 94.8K
- Earning Date
- LGVN 11-04-2025
- BIVI 11-10-2025
- Dividend Yield
- LGVN N/A
- BIVI N/A
- EPS Growth
- LGVN N/A
- BIVI N/A
- EPS
- LGVN N/A
- BIVI N/A
- Revenue
- LGVN $1,437,000.00
- BIVI N/A
- Revenue This Year
- LGVN N/A
- BIVI N/A
- Revenue Next Year
- LGVN N/A
- BIVI N/A
- P/E Ratio
- LGVN N/A
- BIVI N/A
- Revenue Growth
- LGVN N/A
- BIVI N/A
- 52 Week Low
- LGVN $0.59
- BIVI $1.25
- 52 Week High
- LGVN $2.24
- BIVI $31.50
- Technical
- Relative Strength Index (RSI)
- LGVN 30.36
- BIVI 34.56
- Support Level
- LGVN $0.59
- BIVI $1.25
- Resistance Level
- LGVN $0.67
- BIVI $1.48
- Average True Range (ATR)
- LGVN 0.05
- BIVI 0.11
- MACD
- LGVN -0.01
- BIVI -0.01
- Stochastic Oscillator
- LGVN 16.06
- BIVI 24.40
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.